AUTL

Autolus Therapeutics plc AUTL

NasdaqSmall CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,533 of 2,925

Why it scores 28Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$45.69M

Quarter to Jun 30

Net income

$-39.11M

Quarter to Jun 30

Free cash flow

$-25.98M

Quarter to Jun 30

Operating margin

-96.0%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$211.97M total
MAK CAPITAL ONE LLC
$53.79M0.0%
Blackstone Inc.
$32.78M0.0%
Syncona Portfolio Ltd
$26.63M0.0%
ARMISTICE CAPITAL, LLC
$24.00M-5.1%
TFG Asset Management GP Ltd
$15.20M0.0%
SCHRODER INVESTMENT MANAGEMENT GROUP
$12.92M-17.5%
Frazier Life Sciences Management, L.P.
$7.12M0.0%
BNP Paribas Asset Management Holding S.A.
$5.38M0.0%
Laurion Capital Management LP
$5.31M0.0%
RENAISSANCE TECHNOLOGIES LLC
$3.18M-13.7%
BANK OF AMERICA CORP /DE/
$2.57M-13.0%
BlackRock, Inc.
$2.57M+8.3%
UBS Group AG
$2.43M+16.2%
MORGAN STANLEY
$2.02M+33.9%
MILLENNIUM MANAGEMENT LLC
$1.96M+498.3%
Cetera Investment Advisers
$1.85M+2.5%
BALYASNY ASSET MANAGEMENT L.P.
$1.56M+0.1%
JPMORGAN CHASE & CO
$1.51M-2.4%
Alphabet Inc.
$1.12M0.0%
CITADEL ADVISORS LLC
$1.11M+51.5%
Hennion & Walsh Asset Management, Inc.
$722.2K+2.5%
Privium Fund Management B.V.
$581.5K0.0%
JANE STREET GROUP, LLC
$479.8K+22.0%
EDENTREE ASSET MANAGEMENT Ltd
$477.0K0.0%
XTX Topco Ltd
$459.9K+409.6%
See all 84 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/AUTL

Earnings Per Share

13fpro.ai/company/AUTL

Loading ratio trend…

AUTL key financials by period

Reported revenue, net income and operating margin by fiscal year, from Autolus Therapeutics plc's annual filings on SEC EDGAR.

Autolus Therapeutics plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$75.4M$-287.5M—
FY 2024$10.1M$-220.7M—
FY 2023$1.7M$-208.4M—
FY 2019$2.9M$-123.8M—
FY 2018$1.4M$-44.8M—
FY 2017$1.7M$-19.7M—
Source: AUTL filings on SEC EDGAR →

Companies similar to AUTL

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

AUTL insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Autolus Therapeutics plc (AUTL): stock profile, AI score and financials

Autolus Therapeutics plc (AUTL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AUTL at 28.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,533 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Autolus Therapeutics plc reports quarterly revenue of $45.7M, net income of $-39.1M, an operating margin of -96.0%. Top institutional holders of AUTL by reported 13-F value include MAK CAPITAL ONE, Blackstone, Syncona Portfolio Ltd, based on the most recent SEC filings. AUTL trades on the Nasdaq exchange and files with the SEC under CIK 1730463. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AUTL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Autolus Therapeutics plc directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1730463 →